This article has Open Peer Review reports available.
Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis
© Smoyer-Tomic et al.; licensee BioMed Central Ltd. 2012
Received: 2 December 2011
Accepted: 29 May 2012
Published: 15 June 2012
Idiopathic inflammatory myopathies (IIMs) are a rare group of autoimmune syndromes characterized by chronic muscle inflammation and muscle weakness with no known cause. Little is known about their incidence and prevalence. This study reports the incidence and prevalence of IIMs among commercially insured and Medicare and Medicaid enrolled populations in the US.
We retrospectively examined medical claims with an IIM diagnosis (ICD-9-CM 710.3 [dermatomyositis (DM)], 710.4 [polymyositis (PM)], 728.81[interstitial myositis]) in the MarketScan® databases to identify age- and gender-adjusted annual IIM incidence and prevalence for 2004–2008. Sensitivity analysis was performed for evidence of a specialist visit (rheumatologist/ neurologist/dermatologist), systemic corticosteroid or immunosuppressant use, or muscle biopsy.
We identified 2,990 incident patients between 2004 and 2008 (67% female, 17% Medicaid enrollees, 27% aged ≥65 years). Overall adjusted IIM incidence for 2004–2008 for commercial and Medicare supplemental groups combined were 4.27 cases (95% CI, 4.09-4.44) and for Medicaid, 5.23 (95% CI 4.74-5.72) per 100,000 person-years (py). Disease sub-type incidence rates per 100,000-py were 1.52 (95% CI 1.42-1.63) and 1.70 (1.42-1.97) for DM, 2.46 (2.33-2.59) and 3.53 (3.13-3.94) for PM, and 0.73 (0.66-0.81) and 0.78 (0.58-0.97) for interstitial myositis for the commercial/Medicare and Medicaid cohorts respectively. Annual incidence fluctuated over time with the base MarketScan populations. There were 7,155 prevalent patients, with annual prevalence ranging from 20.62 to 25.32 per 100,000 for commercial/Medicare (83% of prevalent cases) and from 15.35 to 32.74 for Medicaid.
We found higher IIM incidence than historically reported. Employer turnover, miscoding and misdiagnosing, care seeking behavior, and fluctuations in database membership over time can influence the results. Further studies are needed to confirm the incidence and prevalence of IIM.
Autoimmune idiopathic inflammatory myopathies (IIMs) consist of a rare group of autoimmune syndromes characterized by chronic muscle inflammation and muscle weakness. They are classified as autoimmune disorders  and have no known cause, although research has implicated infectious agents, medications, and ultraviolet radiation in their etiology . Three main types of IIMs have been proposed based on clinical and histopathologic features: (a) polymyositis (PM), (b) dermatomyositis (DM), and (c) sporadic inclusion body myositis (sIBM). Recent reports have described two new types: nonspecific myositis, and immune-mediated necrotizing myopathy [3–5]. Older reports  also describe an “interstitial myositis” that has not been reported extensively in the literature. Dermatomyositis is the most common of the myositis disorders [2, 7]. Polymyositis is often associated with other connective tissue disorders such as lupus [6, 8, 9]. Treatments for IIMs typically consist of medications such as corticosteroids as first line therapy, (e.g., high doses of oral or intravenous prednisone) and immunosuppressants and immunomodulators (e.g., methotrexate, mycophenolate mofetil, tacrolimus, rituximab) as second line . Physical therapy is also used .
There are few epidemiological studies on IIMs. Until recently, many of the studies of incidence and prevalence of the disease have been on relatively small population studies, often using both medical records and muscle biopsy to ascertain the disease . These types of studies have identified annual myositis (including its sub-types) incidence in the range of 0.1 to 1 per 100,000 person-years (py) [2, 10–15].
One recent study using administrative claims data for Quebec (approximately 7.5 million beneficiaries) estimated prevalence of 21.5 (95% CI: 19.4, 23.9) per 100,000 patients for dermatomyositis and polymyositis, using an IIM case definition of ≥2 outpatient claims with an ICD-9-CM diagnosis recorded for either condition ≤2 months apart and within a 2 year time span, or ≥1 inpatient claim with either ICD-9-CM code, as well as an alternate algorithm with one or more billing code from a rheumatologist . The authors reported higher prevalence for women and older patients. Other studies reporting rates by age and/or sex also have found that incidence rates increase with age (although dermatomyositis affects children as well as adults) and are approximately twice as high among women as among men [2, 6–8, 12]. Separate community-based epidemiologic studies identified a range of prevalence for IIMs, including IIM prevalence of 5.1 per 100,000 in the U.S. , PM prevalence of 3.45 per 100,000 in Olmsted County, Minnesota, USA  and DM prevalence of 21.42 .
Recent work using an U.S. privately insured managed care administrative claims database for 2003–2008 identified a 65/35 female to male ratio of patients with myositis (polymyositis, dermatomyositis, or interstitial myositis) with a median age of 49 years. The overall age- and sex-adjusted myositis incidence rate was 6.57 cases (95% CI, 6.20–6.94) per 100,000 py and was 3.79 for polymyositis, 1.38 for dermatomyositis, and 1.69 for interstitial myositis per 100,000 py, notably higher than the 0.1 to 0.5 per 100,000 myositis incidence reported using smaller, fixed populations [13–15]. Annual myositis prevalence identified in the same study for the period 2003–2008 ranged from 13.99 in 2003 to 17.37 in 2008 per 100,000 py. These prevalence rates are in the range of those reported by Bernatsky  in an administrative claims database in Quebec, suggesting prevalence of myositis, as identified in administrative claims databases, may be in the range of 14–22 cases per 100,000 py.
The aim of the present study is to examine age and sex adjusted incidence and prevalence of IIM using commercial, Medicare and Medicaid populations. This approach offers several advantages. First, it uses a large, geographically diverse U.S. administrative claims database. Since IIMs are rare, the large sample available in the database allows more robust estimates of incidence and prevalence than in many previous studies, which examined IIM incidence and/or prevalence in smaller populations. Second, this approach provides incidence and prevalence estimates by sex and age group, and includes populations with diverse payers (both commercial and Centers for Medicare & Medicaid Services [CMS]). Third, this study includes outpatient as well as inpatient claims, which limits bias in case identification by providing greater sensitivity in incidence and prevalence estimates than would be possible if limited to hospitalization data only. Many of the published incidence and prevalence studies of IIMs that utilized only hospital data  may have under-estimated incidence and prevalence, since myositis often does not require hospitalization.
Study design and subject identification
Patients were selected for the study period 2004–2008 from large administrative claims databases (the MarketScan® Commercial Claims and Encounters Database, Medicare Supplemental and Coordination of Benefit Database, and Medicaid Multi-State Database), geographically representative of the U.S. population. The commercial database contains information for de-identified, standardized medical and outpatient pharmacy claims data for the population under age 65 covered by private-sector health plans (approximately 14 million enrollees annually). Enrollees are covered under 130 unique carriers representing a variety of plan types, including fee-for-service and capitated health plans. The Medicare database contains healthcare experience for 1.6 million individuals (retired or working-aged) with Medicare supplemental insurance paid for by employers. The Medicaid database contains the pooled healthcare experience of approximately 28 million Medicaid enrollees representing 10 different states. Commercial and Medicare enrollees were reported together in the same tables, with incidence and prevalence reported for the combined groups, as their data was contributed by the same group of employers. Incidence and prevalence for Medicaid enrollees were reported separately.
The MarketScan® Databases used in this study are de-identified and fully compliant with the Health Insurance Portability and Accountability Act of 1996. Because this study did not involve the collection, use, or transmittal of individually identifiable data, Institutional Review Board review or approval was not required.
Three types of IIMs were identified for dermatomyositis (DM: ICD-9-CM 710.3), polymyositis (PM: ICD-9-CM 710.4), and interstitial myositis (ICD-6-CM 728.81), using a combination of outpatient and inpatient medical claims (referred to as “diagnostic claims method”), since patients with the condition may not require inpatient treatment . While this method decreases specificity, the increase in sensitivity provides additional insight into the potential scope of persons seeking treatment for IIMs in the U.S. population. Sensitivity analyses, which required criteria in addition to diagnoses (e.g., a specialist visit, IIM medication, or a muscle biopsy) were also performed on annual prevalence and combined incidence (2004–2008).
The incidence date was the earliest date of service between 1/1/2004 and 12/31/2008 with a qualifying medical claim with one of the three IIM diagnoses. A qualifying IIM medical claim was the earliest of an inpatient claim or the first of at least two office or ER visits (including combinations) at least 30 days and less than 365 days apart. The IIM incident cohort was identified as patients at least 18 years of age on the qualifying date of service with an IIM diagnosis, had continuous health plan medical and pharmacy benefits for 1 year before and 1 year after the service date, and had no claim with an IIM diagnosis in a previous year. Incidence was reported annually and for the combined period 2004–2008. The databases extended to 2003, with patients having any evidence of IIMs excluded from the incidence but not excluded from the prevalence cohort. For sensitivity analyses that required either a one year preview or one year follow-up period after the first IIM service date, patient data were evaluated starting in 2003 and extending through 2009.
IIM prevalence was calculated to represent the actual burden of disease at a point of time, and was identified similarly to incidence, except that patients were permitted to have a previous IIM claim. Patients required a qualifying IIM claim during the year, as well as healthplan eligibility for the entire year, to be counted as prevalent in that year. This method identifies prevalence of healthcare utilization for IIM and therefore under-represents IIM prevalence in the MarketScan databases for those patients who have the condition but do not have a qualifying IIM claim in each year for which they maintain healthcare eligibility. However, the strength of this method is that it enables each year to be evaluated separately, and does not result in an artificial increase in prevalence that might be observed if patients with IIM claims in an earlier year in the study continue to contribute to prevalence counts regardless of whether they have an IIM claim in that year.
Patients with IIMs were classified into a general group (any myositis) as well as at least one sub-group: DM, PM, or interstitial myositis. Patients could have more than one type of myositis.
Patient age, gender, urban/rural and geographic region (not available for Medicaid), healthplan type, race (Medicaid only) and payer (commercial, Medicare, Medicaid) were identified on the date of the earliest qualifying IIM claim for both the incident and prevalent cohorts.
Patient comorbidities were identified based on the presence of one inpatient or two or more outpatient claims with a non-rule out ICD-9-CM diagnosis for the comorbidity of interest in the 1 year before the incidence or prevalence date. Medications of interest were identified from outpatient pharmacy claims on or 1 year following the incidence or prevalence date. For the sensitivity analyses, evidence of an outpatient visit to a rheumatologist, dermatologist, or neurologist was captured from medical claims on and 1 year following the index date. Two additional sensitivity criteria were examined: evidence of a medical or outpatient pharmacy claim for a systemic corticosteroid or immunosuppressant (IIM treatment)a on or 1 year following the index date, as well as a medical claim for muscle biopsyb 1 year before, on, or 1 year following the index date. Sensitivity analyses were performed on the combined myositis group as well as on the DM, PM, and interstitial myositis sub-groups.
Incidence and prevalence calculations
For each calendar year between 2004 and 2008, annual incidence was calculated by dividing the number of incident cases by the corresponding annual population at risk. Prevalent patients were excluded from the numerator as well as the denominator for all incidence calculations. To qualify for the denominators, patients had to have no previous qualifying IIM claims, be 18 years during the calendar year of interest, and have continuous medical and pharmacy eligibility for two consecutive years, including the entire calendar year of interest as well as one day in each of the bordering years.
Incidence was also calculated for the period 2004–2008, using the number of unique incident cases during the time period as numerator. The denominator for the overall incidence rate was the total number of person-years at risk between 2004–2008, for a maximum possible of five person-years for continuous enrollees 18 years or older and with no evidence of an IIM during the period.
where N is the total population in person-time (in the relevant MarketScan Database or in the 2000 U.S. Census as indicated) and nij is the person-time in the specific age and sex strata (from the relevant MarketScan Database or the 2000 U.S. Census as indicated).
Annual prevalence was calculated by dividing the number of prevalent cases identified in the data each year by the number of enrollees 18 years or older during the calendar year who had two years of continuous medical and pharmacy eligibility, one of which spanned the entire calendar year of interest, as well as one day in each of the bordering years.
The same methods were applied for sensitivity analyses for the combined 2004–2008 incidence rates and for annual prevalence. Each of the three sensitivity criteria were applied separately as well as combined (patients must have had at least one of the three criteria in addition to being identified as incident or prevalent to contribute to the numerator). For the purposes of this manuscript, each of the three sensitivity analyses as well as the three combined are presented for 2004–2008 incidence for IIMs and the three sub-types. For annual prevalence, only the combined sensitivity analyses are presented, for combined IIMs only, for which to be counted in numerator, patients must have had at least one claim for a muscle biopsy, specialist visit, or immunosuppressant or systemic corticosteroid in the time periods described above, in addition to being identified as prevalent in that year.
Confidence intervals for the crude rates and age- and gender-adjusted rates were calculated using the normal approximation to the binomial distribution. Uncertainty in each yearly age- and gender- adjusted rate was calculated using basic properties of variance, treating each yearly age- and gender-adjusted rate as a simple linear combination of the crude age- and gender-adjusted rates for that same year. Incidence rates were analyzed with the GENMOD procedure in SAS 9.2 using a negative binomial error distribution, log link function, and log of the corresponding denominator as an offset. Equality of crude incidence rates across age groups and gender was tested using likelihood ratio tests (LRT). Sensitivity results were calculated as described above but with the numerators limited to the appropriate subgroup of subjects.
Characteristics of myositis incident patients (2004–2008)
Commercial and Medicare patients
Myositis (Overall) 1
Race/Ethnicity (N, %)
Fee-for-service (N, %)
Clinical Conditions (365 days before index date)
Systemic lupus erythematosus
Other Inflammatory Arthritis/Arthropathies
Medications on or 365 days after index date
Among Medicaid beneficiaries, those with incident IIMs were more likely to be African American (42.9%) than Caucasian (37.6%) or Hispanic (4.9%) (Table1). The race/ethnicity composition of the denominator, however, was 22.8%, 41.8%, and 19.7% respectively, indicating that incidence of IIMs was disproportionately higher among African Americans. Race was not available for the commercial/Medicare cohort. The southern region contributed the greatest share of incident cases to the commercial/Medicare cohort, followed by the north central region, with nearly 85% of cases from an urban area, but these differences reflect the overall distribution of patients in the databases.
The most common comorbid conditions (identified in 15-36% of incident patients) among the commercial/Medicare cohort were hypertension, back problems, other inflammatory arthritis/arthropathies (IA/A), and diabetes. Rates of all reported comorbid conditions were higher among the Medicaid cohort, particularly hypertension (49.9%) and diabetes (31%), and followed by IA/A (29.4%). Conversely, medication usage was lower for nearly all drugs among the Medicaid than the commercial/Medicare cohort. Approximately two-thirds or more of all patients received a systemic corticosteroid, followed by a topical corticosteroid. Methotrexate was received among 26.2% of commercial/Medicare incident patients and among 14.2% of Medicaid patients. Azathioprine and hydroxychloroquine were the next most frequently received, with 14.2% and 12.5% receiving azathioprine and 14.3% and 9.9% receiving hydroxychloroquine among the commercial/Medicare and Medicaid populations respectively. Among both cohorts, 2.5% or fewer used intravenous immunoglobulin, cyclosporine, leflunomide, thalidomide, cyclophosphamide, tacrolimus, or rituximab (Table1).
Myositis incidence (2004–2008)
Commercial and Medicare supplemental database incidence (per 100,000)1
Medicaid database incidence (per 100,000)1
Age- and Gender- adjusted rate4
95% CI (adjusted rate)
Age- and Gender- adjusted rate4
95% CI (adjusted rate)
Myositis (Overall) 2
(LRT χ2 =81.73, df = 6 , p < 0.001)3
(LRT χ2 =38.69, df = 6 , p < 0.001)3
(LRT χ2 =6.77, df = 1, p =0.009)3
(LRT χ2 =9.08, df = 1, p =0.003)3
Adjusted annual incidence for overall IIM ranged from 3.38 (95% CI 3.06-3.71) in 2008 to 5.08 (95% CI 4.61-5.54) in 2005 in the commercial/Medicare database and from 4.47 (95% CI 3.80-5.15) in 2004 to 6.58 (95% CI 5.29-8.41) in 2007 in the Medicaid database. Due to large fluctuations in the size and composition of the denominator associated with variations in MarketScan subscribers (particularly in the Medicaid database), comparisons over time are not meaningful, and no trend analysis was undertaken. Crude and adjusted IIM incidence rates were higher among females than males in both databases. Among commercial/Medicare enrollees, adjusted incidence among females was 5.38 (5.11-5.66) and among males was 3.07 (2.85-3.28) per 100,000 py; LRT χ2 =6.77, df = 1, p =0.009 as shown in Table2. Among Medicaid enrollees, rates were 6.68 (6.00-7.36) for females and 3.67 (2.96-4.37) for males LRT χ2 =9.08, df = 1, p =0.003 (Table2). IIM incidence rates by age group varied between the two cohorts. In the commercial/Medicare database, the 65–74 years cohort had the highest rates (9.30 per 100,000 py; 95% CI 8.38-10.22), LRT χ2 =81.73, df = 6 , p < 0.001, while in the Medicaid database, the 55–64 cohort had the highest rates (9.72 per 100,000 py; 95% CI 7.93-11.52), LRT χ2 =38.69, df = 6 , p < 0.001 (Table2).
Sensitivity Analysis of Incidence Rates per 100,000 person-years (2004–2008)
Commercial and Medicare supplemental database
Age & Gender adjusted rate
95% CI for adjusted rate
Age & Gender adjusted rate
95% CI for adjusted rate
Base case analysis (IIMs)
Presence of muscle biopsy one year prior to or one year following index date
Presence of specialist visit on index date or in the year following
Presence of immunosuppressants and/or systemic corticosteroids one year following index date
Presence of any of the above (combined sensitivity criteria)
The combined sensitivity analysis identified between 85% and 87% of incident DM and PM commercial/Medicare patients as compared to the diagnostic claims method, and only 38% of those with incident interstitial myositis. In the Medicaid population the sensitivity analysis identified 66% of incident DM patients, 74% of incident PM patients, and 46% of incident interstitial myositis patients reported as incident using the diagnostic claims method. Among the individual sensitivity criteria, specialist visits on or one year after the incidence date identified the lowest percentage of incident patients and immunosuppressants or systemic corticosteroids on or one year after identified the largest percentage (Table3).
Characteristics of Myositis Prevalent Patients (2004–2008)
Commercial and Medicare patients
Myositis (Overall) 1
Race/Ethnicity (N, %)
Fee-for-service (N, %)
Systemic lupus erythematosus
Other Inflammatory Arthritis/Arthropathies
Medications on or 365 days after index date
Prevalent cases were distributed relatively evenly by year among the commercial/Medicare database, but in the Medicaid database were highest in 2004 followed by 2005, which reflected the notably higher base population in those years rather than any observed trend in prevalence over time. As with incidence, more than 2/3 of the prevalent population were females (68% among the commercial/Medicare and 76% among the Medicaid databases). The mean age of prevalent patients was slightly lower than that of incident patients. Among commercially insured or Medicare enrolled females, the mean age was 54.5 years (SD 15.2) and among males, 55.4 years (SD 14.7). Among Medicaid beneficiaries (a younger group overall), the mean age for females was 49 years (SD 16.4) and for males was 47.7 years (SD 16.3). As with incidence, Medicaid enrollees with prevalent IIMs were disproportionately African American (44.5%) as compared to Caucasian (36.2%) or Hispanic (6.7%). The regional and urban/rural distribution of prevalent cases was similar to incident cases in the commercial/Medicare population, with a slightly higher percentage in the southern and western regions in the prevalent cohort than in the incident cohort (Table4). These distributions reflected the source databases.
Comorbid conditions identified in the prevalent population were similar in proportion to those identified in the incident population with hypertension, back problems, other inflammatory arthritis/arthropathies, and diabetes the most common conditions among both the commercial/Medicare and Medicaid cohorts. Medication usage for nearly all reported drugs was slightly higher among the prevalent than the incident populations for both databases (Table4).
Annual myositis prevalence (2004–2008): Base case and sensitivity analysis
Commercial and Medicare supplemental database (per 100,000 individuals)
Annual prevalence 95% CI
Medicaid database (per 100,000 individuals)
Annual prevalence 95% CI
Base case analysis
Sensitivity analysis 1
IIMs are a rare condition, and little is known about the extent of their incidence and prevalence in the U.S. population. In this study, we used the MarketScan Commercial, Medicare, and Medicaid administrative claims databases to identify incidence and prevalence of IIMs based on medical claims with an ICD-9-CM diagnosis indicating DM, PM, or interstitial myositis. Administrative claims analyses, such as the one performed here, have the benefit of data contributed by very large populations seeking medical care, which can be used to identify rare conditions and shed additional light into incidence and prevalence. The limitation of these methods is the flip side of the benefit coin, in that unless patients seek care for their IIM, they will not be correctly identified as incident or prevalent. In addition, misdiagnosis or recording errors can result in under- or over-reporting of the condition. Another limitation in using administrative claims databases for identifying incidence and prevalence is that the results are sensitive to the methods used to identify the population denominator.
Due to the dynamic nature of the employer-based and Medicaid administrative claims databases used here, the annual values are most informative as snapshots providing a range of estimates among a fluctuating population, rather than indicative of trends in incidence or prevalence of myositis in the U.S. population. Another consideration particular to employer-based databases is that employees with chronic conditions may be less likely to change employers and risk changes to their healthcare coverage, and therefore may stay in the data longer than other employees at the same employer.
Both the current study and one using very similar methods (1 inpatient or 2 outpatient claims for PM, DM, or interstitial myositis) in another U.S. managed care administrative claims database  reported notably higher incidence of IIMs than the 0.1 to 1 per 100,000 py reported in community-based studies using smaller populations [2, 10–15]. This study identified age- and sex-adjusted incidence rates of 4.27 (commercial/Medicare) and 5.23 (Medicaid) per 100,000 py for the period 2004–2008, while Furst et al.  reported adjusted incidence rates of 6.57 (95% CI, 6.20–6.94) per 100,000 py for combined IIMs. For DM, we identified adjusted incidence rates of 1.52 and 1.70 per 100,000 py in the commercial/Medicare and Medicaid databases respectively, which were relatively comparable to the 1.38 per 100,000 py reported by Furst et al. . Incidence rates for PM were also comparable at 2.46 (commercial/Medicare) and 3.53 (Medicaid) in this study versus 3.79 per 100,000 py in Furst et al . These rates were similar to the prevalence of PM of 3.45 per 100,000 py identified by Wilson et al. . Interstitial myositis varied among the two studies, in that it was the least common of the three types of IIM, with adjusted incidence of 0.73 and 0.78 per 100,000 py in the two databases compared to 1.69 per 100,000 py reported in Furst et al., in which DM rather than interstitial myositis was the least common type of myositis. Due to very low counts of interstitial myositis, along with limited consistent clinical information about the condition and its diagnosis, incidence and prevalence for that sub-type should be interpreted with caution.
In contrast to incidence estimates, the prevalence of IIMs identified by medical claim (20.62 to 25.32 per 100,000 py in commercial/Medicare and 15.35 to 32.74 in Medicaid) in this study is quite comparable to that identified using a contemporary administrative claims database in Quebec (combined DM and PM annual prevalence in 2003 of 21.5 (95% CI 19.4-23.9) per 100,000 py . The prevalence of IIMs identified in this study is, however, somewhat higher than prevalence of combined DM, PM and interstitial myositis given in Furst et al.  of 9.54 in 2003 and 13.61 in 2008, albeit the lower prevalence in Furst et al. could be associated with a younger population (9% of prevalent cases were ≥ 65 years in their IIM cohort vs. 24% ≥ 65 years in the commercial/Medicare and 16% of prevalent cases in the Medicaid IIM cohorts). Notably, all three administrative claims studies reported annual prevalence that was nearly 2- to 6-fold higher than that reported in one earlier study from 2003 . It is possible that with increased awareness of IIMs, the condition may be increasingly recognized and diagnosed, and thus showing up more frequently in administrative claims databases over the past decade than in previous decades.
When the 2004–2008 age- and sex-adjusted incidence rates for the two databases are projected to the U.S. population ages 18 years and older, the expected number of incident cases per year ranges from 8,919 to 10,937 (based on the commercial/Medicare and Medicaid incidence rates respectively, standardized to the 2000 U.S. Census). Using the combined sensitivity analysis (e.g., IIM incidence along with one or more of the three sensitivity criteria), the expected number of incident cases per year among adults in the U.S. ranges from 6,871 (commercial/Medicare incidence rates) to 7,312 (Medicaid incidence rates).
Extrapolating the annual prevalence of persons seeking medical care for IIMs reported here to the U.S. population (as of the 2000 U.S. Census) aged 18 years and older from the commercial/Medicare cohort results in a range of an estimated 43,000 to 53,000 treated cases per year, or, after employing any one of the three sensitivity criteria, an estimated 38,000 to 45,000 treated cases per year. If the Medicaid annual prevalence is used, estimated annual U.S. IIM prevalence ranges from approximately 32,000 to 68,000 using IIM claims only, or 26,000 to 60,000 treated cases using any of the three sensitivity criteria.
This study is unique in its incorporation of three payer groups: commercially insured, Medicare enrollees (with employer paid supplemental insurance), and Medicaid enrollees. The different incidence and prevalence identified in the commercial/Medicare versus Medicaid populations in this analysis may be a result of differences in patients’ healthcare-seeking behaviors as well as in reimbursement and practice patterns rather than the underlying difference in disease incidence and prevalence among the two populations. The relative similarity in prevalence and incidence identified in separate studies conducted in different administrative claims databases indicates that these variations are common in these types of databases. Another consideration unique to the current study is the high incidence and prevalence among African Americans identified in the Medicaid database. Since race/ethnicity is unknown in the commercial and Medicare cohorts, it is unknown to what extent differences in racial composition between the two cohorts may influence the observed incidence and prevalence of myositis. Additional studies of IIM incidence and prevalence by race/ethnicity are needed.
The incidence and prevalence estimates reported here are in the range of those reported in other studies using administrative claims databases. Like those studies, the estimates reported here are based on the presence of a medical claim with the ICD-9-CM diagnoses of interest and are a function of individuals seeking medical care and physician reporting of diagnosis. This study used an algorithm to exclude rule-out diagnoses; nevertheless, administrative claims are not a substitute for a complete medical record for the study population and thus mis-diagnoses are possible. Since a one year “clean” period was required to qualify as incident, incidence may have been over-estimated if patients already had an IIM but did not receive medical care in the preceding year. In addition, prevalence was expected to be under-estimated as it was defined by evidence of a qualifying medical claim with an IIM diagnosis in each year. Patients with the condition who did not seek medical care in a given year would not be captured in the prevalence estimates. Finally, employer turnover, miscoding and misdiagnosing, care seeking behavior, and fluctuations in database membership over time can influence the results. Further studies are needed to confirm the incidence and prevalence of IIM.
Among 2,990 incident IIM patients between 2004 and 2008, overall adjusted IIM incidence for 2004–2008 for commercial and Medicare supplemental groups combined were 4.27 cases per 100,000 py, and for Medicaid were 5.23 cases per 100,000 py. The highest incidence among disease sub-types was for PM, at 2.46 (commercial/Medicare) and 3.53 (Medicaid) new cases per 100,000 py. Annual IIM prevalence ranged from 20.62 to 25.32 per 100,000 for commercial/Medicare (83% of prevalent cases) and from 15.35 to 32.74 for Medicaid. Although this study found higher IIM incidence than historically reported based on smaller, localized populations, the similarity of the findings of the current study with others in the literature using administrative claims databases suggests that IIM incidence in the U.S. population is in the range of 3 to 7 new cases per 100,000 py and that prevalence as measured by claims for IIM treatment is in the range of 32,000 to 68,000 per year. Future studies using alternate administrative claims databases will be helpful in narrowing down the range of incidence and prevalence estimates, and additional analyses of the cohorts identified as incident and prevalent using chart review would be beneficial in confirming IIM diagnoses, particularly for the three sub-types.
aImmunosuppressants included methotrexate, azathioprine, hydroxychloroquine, intravenous immunoglobulin, cyclosporine, mycophenolate mofetil, leflunomide, thalidomide, cyclophosphamide, tacrolimus, and rituximab.
bMuscle biopsy codes included ICD-9-CM Procedure 83.21 or CPT codes 10021, 10022, 20200, 20205, 20206, 21550, 21925, 23066, 24066, 25066, 27041, 27324, or 27614.
The authors acknowledge Jon Fryzek for his assistance with epidemiological methods and the following Thomson Reuters employees: Cortney Hayflinger and Robert Fowler for their assistance in extracting the data, Gregory Lenhart for statistical analysis, and Katy Pan for formatting and editorial assistance. MedImmune LLC. provided the funding for this study, including the study design, patient selection criteria, analysis, interpretation of the data, writing the manuscript, and the decision to submit the manuscript for publication. Thomson Reuters owns and maintains the MarketScan® Databases used in this analysis.
- National Institute of Neurological Disorders and Stroke (NINDS): National Institutes of Health. 2010, Available: http://www.ninds.nih.gov/disorders/inflammatory_myopathies/detail_inflammatory_myopathies.htm Google Scholar
- Prieto S, Grau JM: The geoepidemiology of autoimmune muscle disease. Autoimmun Rev. 2010, 9: A330-4. 10.1016/j.autrev.2009.11.006.View ArticlePubMedGoogle Scholar
- Amato AA, Barohn RJ: Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry. 2009, 80: 1186-93. 10.1136/jnnp.2009.173823.View ArticlePubMedGoogle Scholar
- Amato AA, Barohn RJ: Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry. 2009, 80: 1060-1068. 10.1136/jnnp.2008.169375.View ArticlePubMedGoogle Scholar
- Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR: 119th ENMC international workshop.Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004, 14: 337-345. 10.1016/j.nmd.2004.02.006.View ArticlePubMedGoogle Scholar
- Pongratz D, Späth M, Fischer P: Myositis as a cause of muscle pain. J Musculoskeletal Pain. 1999, 7: 121-129. 10.1300/J094v07n01_12.View ArticleGoogle Scholar
- Mammen AL: Dermatomyositis and poly myositis: Clinical presentation, autoantibodies, and pathogenesis. Ann NY Acad Sci. 2010, 1184: 34-153.View ArticleGoogle Scholar
- Mastaglia FL, Phillips BA: Idiopathic inflammatory myopathies: Epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am. 2002, 28: 723-741. 10.1016/S0889-857X(02)00021-2.View ArticlePubMedGoogle Scholar
- Hengstman GJD, van den Hoogen FHJ, van Engelen BGM: Treatment of the inflammatory myopathies: Update and practical recommendations. Expert Opin. Pharmacother. 2009, 10: 1183-1190. 10.1517/14656560902913815.View ArticlePubMedGoogle Scholar
- Wilson FC, Ytterberg SR, St Sauver JL, Reed AM: Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol. 2008, 35: 445-7.PubMedGoogle Scholar
- Briani C, Doria A, Sarzi- Puttini P, Dalakas MC: Update on idiopathic inflammatory myopathies. Autoimmunity. 2006, 39: 161-170. 10.1080/08916930600622132.View ArticlePubMedGoogle Scholar
- Dalakas MC, Hohlfeld R: Polymyositis and dermatomyositis. Lancet. 2003, 362: 971-82. 10.1016/S0140-6736(03)14368-1.View ArticlePubMedGoogle Scholar
- Choy EHS, Isenberg DA: Treatment of dermatomyositis and polymyositis. Rheumatology. 2002, 41: 7-13.View ArticlePubMedGoogle Scholar
- Oddis CV, Conte CG, Steen VD, Medsger JA: Incidence of polymyositis- dermatomyositis. J Rheumatol. 1990, 17: 1329-34.PubMedGoogle Scholar
- Benbassat J, Geffel D, Zlotnick A: Epidemiology of polymyositis-dermatomyositis in Israel, 1960–76. Isr J Med Sci. 1980, 16: 197-200.PubMedGoogle Scholar
- Bernatsky S, Joseph L, Pineau CA, Belisle CA, Boivin JF, Banerjee D, Clarke AE: Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis. 2009, 68: 1192-96. 10.1136/ard.2008.093161.View ArticlePubMedGoogle Scholar
- Cooper GS, Stroehla BC: The epidemiology of autoimmune diseases. Autoimmun Rev. 2003, 2: 119-125. 10.1016/S1568-9972(03)00006-5.View ArticlePubMedGoogle Scholar
- Bendewald MJ, Wetter DA, Li X, Davis M: Incidence of dermatomyositis and clinically amyopathic dermatomyositis. Arch Dermatol. 2010, 146: 26-30. 10.1001/archdermatol.2009.328.View ArticlePubMedGoogle Scholar
- Furst DE, Amato AA, Iorga SR, Gajira K, Fernandes A: Epidemiology of idiopathic inflammatory myopathy in a large United States managed care population [abstract]. Arthritis Rheum. 2011, 63: S726-Google Scholar
- Insinga RA, Itzeler RF, Pellissier JM, Saddier P, NIkas AA: The incidence of herpes zoster in a United States administrative datablase. J Gen Intern Med. 2005, 20: 748-753. 10.1111/j.1525-1497.2005.0150.x.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/13/103/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.